{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-26-000045","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2026-08-03T20:03:40+00:00","discovered_at":"2026-08-03T20:04:18.198483+00:00","generated_at":"2026-08-03T20:04:24.725893+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inspire Medical Q2 revenue down 7.6% to $200.6M; raises FY2026 guidance; announces Project Horizon restructuring","bullets":["Q2 revenue $200.6M (-7.6% YoY); diluted EPS $0.01, adjusted diluted EPS $0.14.","Gross margin 85.5% (+150 bps); operating cash flow $23.2M vs $2.7M prior year.","Raised FY2026 revenue guidance to $835M-$875M; adjusted diluted EPS guidance $1.05-$1.45.","Announced Project Horizon restructuring to generate $30M annualized growth investment capacity; expects $20M-$25M pre-tax charges.","Cash and investments $415.2M as of June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-26-000045","json":"https://secwatch.observer/filing/0001609550-26-000045.json","markdown":"https://secwatch.observer/filing/0001609550-26-000045.md","text":"https://secwatch.observer/filing/0001609550-26-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955026000045/0001609550-26-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955026000045/insp-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:04:24.725893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}